General Information of Drug (ID: DM0DQM5)

Drug Name
Amlexanox
Synonyms
ANW; Amlenanox; Amlexanoxo; Amlexanoxum; Amoxanox; Aphthasol; Aptheal; Apthera; Elics; OraDisc; OraRinse; Solfa; Amlexanoxo [Spanish]; Amlexanoxum [Latin]; GlaxoSmithKline brand of amlexanox; OraDisc A; AA 673; CHX 3673; AA-673; Aphthasol (TN); CHX-3673; Solfa (TN); Amlexanox [USAN:INN:JAN]; Amlexanox (JAN/USAN/INN); 2-Amino-7-isopropyl-5-oxo-5H-(1)benzopyrano(2,3-b)pyridine-3-carboxylic acid; 2-amino-5-oxo-7-(propan-2-yl)-5H-chromeno[2,3-b]pyridine-3-carboxylic acid; 2-amino-5-oxo-7-propan-2-ylchromeno[2,3-b]pyridine-3-carboxylic acid; 2-amino-7-(1-methylethyl)-5-oxo-5H-chromeno[2,3-b]pyridine-3-carboxylic acid; 2-amino-7-isopropyl-5-oxo-5H-(1)benzopyrano(2,3b)pyridine-3-carboxylic acid
Indication
Disease Entry ICD 11 Status REF
Respiratory tract inflammation CA07 Approved [1]
Therapeutic Class
Antiulcer Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 298.29
Logarithm of the Partition Coefficient (xlogp) 3.1
Rotatable Bond Count (rotbonds) 2
Hydrogen Bond Donor Count (hbonddonor) 2
Hydrogen Bond Acceptor Count (hbondacc) 6
ADMET Property
Half-life
The concentration or amount of drug in body reduced by one-half in 3.5 +/-1.1 hours [2]
Metabolism
The drug is metabolized to hydroxylated and conjugated metabolites []
Chemical Identifiers
Formula
C16H14N2O4
IUPAC Name
2-amino-5-oxo-7-propan-2-ylchromeno[2,3-b]pyridine-3-carboxylic acid
Canonical SMILES
CC(C)C1=CC2=C(C=C1)OC3=NC(=C(C=C3C2=O)C(=O)O)N
InChI
InChI=1S/C16H14N2O4/c1-7(2)8-3-4-12-9(5-8)13(19)10-6-11(16(20)21)14(17)18-15(10)22-12/h3-7H,1-2H3,(H2,17,18)(H,20,21)
InChIKey
SGRYPYWGNKJSDL-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
2161
ChEBI ID
CHEBI:31205
CAS Number
68302-57-8
DrugBank ID
DB01025
TTD ID
D0G5UB
ACDINA ID
D00836
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Heat shock protein 90 alpha (HSP90A) TT78R5H HS90A_HUMAN Inhibitor [3]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Glutathione peroxidase 1 (GPX1) OTE2O72Q GPX1_HUMAN Protein Interaction/Cellular Processes [4]
Inhibitor of nuclear factor kappa-B kinase subunit epsilon (IKBKE) OT5VYOSM IKKE_HUMAN Gene/Protein Processing [5]
Regulator of nonsense transcripts 1 OTAIA3HP RENT1_HUMAN Protein Interaction/Cellular Processes [4]
Serine/threonine-protein kinase TBK1 (TBK1) OT1P06NV TBK1_HUMAN Gene/Protein Processing [5]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Respiratory tract inflammation
ICD Disease Classification CA07
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Heat shock protein 90 alpha (HSP90A) DTT HSP90AA1 3.96E-01 0.18 0.48
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Allura red AC dye E00338 33258 Colorant
Benzyl alcohol E00010 244 Antimicrobial preservative; Solvent
FD&C blue no. 1 E00263 19700 Colorant
Glyceryl monostearate E00310 24699 Emollient; Emulsifying agent; Emulsion stabilizing agent; Solubilizing agent; Surfactant; Viscosity-controlling agent
methylparaben E00149 7456 Antimicrobial preservative
Sodium benzoate E00432 517055 Antimicrobial preservative; lubricant
Carboxymethylcellulose sodium E00621 Not Available Adsorbent; Binding agent; Disintegrant; Emulsifying agent; Suspending agent; Viscosity-controlling agent
Gelatin E00630 Not Available Other agent
Hypromellose E00634 Not Available Coating agent
Povidone E00667 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Propylene glycol E00040 1030 Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Propylene glycol monostearate E00239 14878 Emollient; Emulsifying agent; Surfactant
Water E00035 962 Solvent
Ethyl cellulose E00699 Not Available Coating agent; Microencapsulating agent; Binding agent; Diluent; Viscosity-controlling agent
Hydroxyethyl cellulose E00700 Not Available Coating agent; Suspending agent; Binding agent; Viscosity-controlling agent
Pectin E00711 Not Available Emulsifying agent; Gelling agent; Viscosity-controlling agent
Pregelatinized starch E00674 Not Available Binding agent; Diluent; Disintegrant
⏷ Show the Full List of 17 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Amlexanox 2mg Patch 2mg Patch Topical
Amlexanox 5% paste 5% Paste Dental
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7113).
2 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
3 Hsp90 is a direct target of the anti-allergic drugs disodium cromoglycate and amlexanox. Biochem J. 2003 Sep 1;374(Pt 2):433-41.
4 Premature termination codon readthrough in human cells occurs in novel cytoplasmic foci and requires UPF proteins. J Cell Sci. 2017 Sep 15;130(18):3009-3022. doi: 10.1242/jcs.198176. Epub 2017 Jul 25.
5 Hydroxychloroquine-inhibited dengue virus is associated with host defense machinery. J Interferon Cytokine Res. 2015 Mar;35(3):143-56. doi: 10.1089/jir.2014.0038. Epub 2014 Oct 16.